AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious

Related Keywords

Japan ,Australia ,South Korea ,Japanese ,Anne Bowdidge ,Eric Easom ,Therapeutics Inc ,National Institute Of Allergy ,Lung Disease In European Union ,Nasdaq ,Development Rd Expenses ,European Union ,Infectious Disease Society Of America Idsa Idweek ,Devices Agency ,European Commission ,Japanese Pharmaceuticals ,Medical Devices Agency ,Chief Executive ,National Institute ,Infectious Disease ,Recent Business Updates ,Epetraborole Pivotal Phase ,Fast Track ,Qualified Infectious Disease Product ,Epetraborole Data ,Japanese Subjects ,Supports Use ,New Epetraborole Data ,Infectious Disease Society ,Orphan Medicinal Product Designation ,Fourth Quarter ,Full Year ,Private Securities Litigation Reform Act ,Press Release , ,